Genzyme begins dosing in phase 3 study of Clolar in AML

By Lisa Kerner

Charlotte, N.C., Sept. 6 - Genzyme Corp. said the first of 376 patients has been treated in a new phase 3 clinical trial examining the safety and effectiveness of Clolar (clofarabine) in older patients with acute myelogenous leukemia (AML).

The effectiveness of one dose of 40 mg/m2 per day of Clolar combined with 1 g/m2 per day of Ara-C, will be compared with 1g/m2 per day of Ara-C combined with a placebo.

Primary endpoint of the study is overall survival.

"The start of this new clinical study is an important next step in our plan to broaden Clolar's label to benefit a larger patient population and address multiple lines of adult AML," said Mark Enyedy, senior vice president of Genzyme Oncology, in a news release.

Genzyme is a Cambridge, Mass.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.